Japan's Central Social Insurance Medical Council approved public health-insurance coverage for Amshapri, an iPS-cell regenerative-medicine product for Parkinson’s disease [1].
This decision marks the first time in the world that a regenerative medicine product derived from induced pluripotent stem cells (iPS cells) will be commercially available to patients under a national health-insurance system [1, 4].
The council, which serves as the advisory body to the Ministry of Health, Labour and Welfare, met Aug. 8, 2024, to finalize the insurance coverage [1, 2, 3]. During this meeting, the body set the price for the therapy at approximately ¥55.3 million [1].
Amshapri is one of two iPS-cell regenerative-medicine products that received conditional manufacturing-sale approval in March 2024 [1, 5]. The other approved product, Reharth, is designed to treat heart failure [5].
While the council has approved the price, some reports indicated a discrepancy regarding the timeline of these discussions. While the majority of sources cite the approved price of ¥55.3 million [1], other reports said that price discussions had only recently begun and would take several months to resolve [1].
The approval follows a rigorous process to transition iPS-cell technology from laboratory research to practical clinical application. By integrating the treatment into the public insurance framework, the Japanese government aims to reduce the financial barrier for patients seeking advanced regenerative therapies.
“The decision marks the first time in the world that a regenerative medicine product derived from induced pluripotent stem cells will be commercially available.”
The integration of iPS-cell therapies into Japan's public insurance system represents a significant shift in the commercialization of regenerative medicine. By establishing a reimbursement price for Amshapri, Japan is creating a financial blueprint for future stem-cell treatments. This move accelerates the transition of high-cost, experimental biotechnology into standard clinical care, potentially positioning Japan as the global leader in the practical application of iPS-cell technology.
